Table 1.
COVID-19 outcomes according to pre-existing schizophrenia.
References | Article type | Study population | Prevalence of schizophrenia | Outcome | Risk |
---|---|---|---|---|---|
Fond et al. (13) | Cohort study | 50,750 | 1.60% | In-hospital mortality | 1.30 (1.08–1.56)* |
Fond et al. (13) | Cohort study | 50,750 | 1.60% | ICU admission | 1.58 (1.09–2.3)* |
Lee et al. (14) | Cohort study | 7,160 | NA | SARS-CoV-2 infection | 1.00 (0.93–1.08)* |
Lee et al. (14) | Cohort Study | 7160 | NA | Composite | 2.27 (1.50–3.41)* |
Wang et al (15). | Retrospective | 61,783,950 | NA | SARS-CoV-2 infection | 7.34 (6.65 −8.10)* |
Ji et al. (16) | Retrospective | 219,961 | 3.6% | SARS-CoV-2 infection | 1.6–1.7 (ORR) |
Nemani et al. (17) | Retrospective | 7,348 | 1%** | In-hospital mortality | 2.67 (1.48–4.8)* |
Taquet et al. (18) | Retrospective | 62,354 | 2% | SARS-CoV-2 infection | 1.17 (1.02–1.33)* |
Composite, Death or ICU admission or invasive ventilation; ICU, Intensive care unit; NA, Not given;
Odds ratio (95% CI);
Schizophrenia spectrum disorder; ORR, Odds ratio range (95% CI not given).